Authors: | Badar, T.; Nanaa, A.; Atallah, E.; Shallis, R. M.; Guilherme, S. D. C. C.; Goldberg, A. D.; Saliba, A. N.; Patel, A.; Bewersdorf, J. P.; DuVall, A. S.; Bradshaw, D.; Abaza, Y.; Murthy, G. S. G.; Palmisiano, N.; Zeidan, A. M.; Kota, V.; Litzow, M. R. |
Title: | Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND) |
Keywords: | adult; cancer survival; controlled study; event free survival; aged; unclassified drug; gene mutation; major clinical study; methylation; overall survival; leukemia, myeloid, acute; allogeneic stem cell transplantation; cancer combination chemotherapy; monotherapy; antineoplastic agent; letter; antineoplastic combined chemotherapy protocols; cohort analysis; cytogenetics; data base; protein p53; tumor suppressor gene; drug combination; sulfonamides; tumor suppressor protein p53; leukemia remission; comparative effectiveness; clinical outcome; acute myeloid leukemia; hypomethylating agent; humans; human; male; female; median survival time; venetoclax; malignant neoplasm; bridged bicyclo compounds, heterocyclic |
Journal Title: | Blood Cancer Journal |
Volume: | 14 |
ISSN: | 2044-5385 |
Publisher: | Nature Publishing Group |
Date Published: | 2024-02-20 |
Start Page: | 32 |
Language: | English |
DOI: | 10.1038/s41408-024-01000-2 |
PUBMED: | 38378617 |
PROVIDER: | scopus |
PMCID: | PMC10879201 |
DOI/URL: | |
Notes: | Letter -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PubMed and PDF -- Source: Scopus |